File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Epigenetic inactivation of the miR-34a in hematological malignancies
Title | Epigenetic inactivation of the miR-34a in hematological malignancies |
---|---|
Authors | |
Keywords | Malignancy |
Issue Date | 2010 |
Citation | The 15th Congress of the European Hematology Association (EHA), Barcelona, Spain, 10-13 June 2010. How to Cite? |
Abstract | BACKGROUND : miR-34a is a transcriptional target of p53, and implicated in carcinogenesis. AIM: We studied the role of miR-34a methylation in a panel of hematological malignancies including acute leukemia (AML, ALL), chronic leukemia (CLL and CML), multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL). METHODS: The methylation status of miR-34a promoter was studied in 12 cell lines and 188 diagnostic samples by methylation-specific PCR. RESULTS: miR-34a promoter was unmethylated in normal controls but methylated in 75% lymphoma and 37% myeloma cell lines. Hypomethylating treatment led to re-expression of pri-miR-34a transcript in lymphoma cells with homozygous miR-34a methylation. In primary samples at diagnosis, miR-34a methylation was detected in 4% CLL, 5.5% MM samples, and 18.8% of NHL at diagnosis but none of ALL, AML and CML (p=0.011). In MM patients with paired samples, miR-34a methylation status remained unchanged at progression. Amongst lymphoid malignancies, miR-34a was preferentially methylated in NHL (p=0.018), in particular natural killer/T cell (NK/T cell) lymphoma. SUMMARY: Amongst hematological malignancies, miR-34a methylation is preferentially hypermethylated in NHL, in particular NK/T cell lymphoma, in a tumor-specific manner, therefore the role of miR-34a in lymphomagenesis warrants further study. |
Description | Poster Session 1: Developmental Biology & Genomics |
Persistent Identifier | http://hdl.handle.net/10722/126433 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chim, JCS | en_HK |
dc.contributor.author | Wong, KY | en_HK |
dc.contributor.author | Qi, Y | en_HK |
dc.date.accessioned | 2010-10-31T12:28:20Z | - |
dc.date.available | 2010-10-31T12:28:20Z | - |
dc.date.issued | 2010 | en_HK |
dc.identifier.citation | The 15th Congress of the European Hematology Association (EHA), Barcelona, Spain, 10-13 June 2010. | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/126433 | - |
dc.description | Poster Session 1: Developmental Biology & Genomics | - |
dc.description.abstract | BACKGROUND : miR-34a is a transcriptional target of p53, and implicated in carcinogenesis. AIM: We studied the role of miR-34a methylation in a panel of hematological malignancies including acute leukemia (AML, ALL), chronic leukemia (CLL and CML), multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL). METHODS: The methylation status of miR-34a promoter was studied in 12 cell lines and 188 diagnostic samples by methylation-specific PCR. RESULTS: miR-34a promoter was unmethylated in normal controls but methylated in 75% lymphoma and 37% myeloma cell lines. Hypomethylating treatment led to re-expression of pri-miR-34a transcript in lymphoma cells with homozygous miR-34a methylation. In primary samples at diagnosis, miR-34a methylation was detected in 4% CLL, 5.5% MM samples, and 18.8% of NHL at diagnosis but none of ALL, AML and CML (p=0.011). In MM patients with paired samples, miR-34a methylation status remained unchanged at progression. Amongst lymphoid malignancies, miR-34a was preferentially methylated in NHL (p=0.018), in particular natural killer/T cell (NK/T cell) lymphoma. SUMMARY: Amongst hematological malignancies, miR-34a methylation is preferentially hypermethylated in NHL, in particular NK/T cell lymphoma, in a tumor-specific manner, therefore the role of miR-34a in lymphomagenesis warrants further study. | - |
dc.language | eng | en_HK |
dc.relation.ispartof | Congress of the European Hematology Association, EHA 2010 | - |
dc.subject | Malignancy | - |
dc.title | Epigenetic inactivation of the miR-34a in hematological malignancies | en_HK |
dc.type | Conference_Paper | en_HK |
dc.identifier.email | Chim, JCS: jcschim@hku.hk | en_HK |
dc.identifier.email | Qi, Y: blackfin561@163.com | en_HK |
dc.identifier.hkuros | 172209 | en_HK |
dc.description.other | The 15th Congress of the European Hematology Association (EHA), Barcelona, Spain, 10-13 June 2010. | - |